↓ Skip to main content

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19

Overview of attention for article published in JAMA: Journal of the American Medical Association, July 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
Published in
JAMA: Journal of the American Medical Association, July 2021
DOI 10.1001/jama.2021.9508
Pubmed ID
Authors

Roberto Caricchio, Antonio Abbate, Ivan Gordeev, Jamie Meng, Priscilla Y Hsue, Tuhina Neogi, Roberto Arduino, Daria Fomina, Roman Bogdanov, Tatiana Stepanenko, Pilar Ruiz-Seco, Andrés Gónzalez-García, Yu Chen, Yuhan Li, Sarah Whelan, Stephanie Noviello, Stanislas Faguer, Alberto Papi, Fabiano Di Marco, Alina S. Agafina, Anastasia S. Mochalova, Dmitry A. Lioznov, Dmitry V. Privalov, Konstantin V. Trufanov, Tatiana I. Martynenko, José Luis Pablos-Alvarez, Segundo Bujan, Vicente Estrada, Xavier Solanich-Moreno, Harpal Randeva, Hasan Tahir, Helen J. Lachmann, Sinisa Savic, Vishal Patel, Anne Lachiewicz, Babafemi Taiwo, Daniel R. Kuritzkes, Jeffrey M. Jacobson, Joel V. Chua, Mihran Shirinian, Monica Fung, Turner Overton, Vinay Malhotra, Eugene Kissin, Natalia Morone, Manish Sagar, Marcin Trojanowski, Parag Desai, Samuel Krachman, Daniel Salerno, Jeffrey Stewart, Matthew Zheng, Rohit Gupta, Kartik Shenoy, Nathaniel Marchetti, Maulin Patel, Fredric Jaffe, Junad Chowdhury, James Brown, Maria Elena Vega-Sanchez, Stephen Codella, Steven Verga, Gustavo Fernandez-Romero, Janpreet Mokha, Gerard J. Criner, Parth Rali, Sameep Sehgal, Zachariah Dorey-Stein, Aditi Satti, Eduardo Dominguez-Castillo, Nicole Mills, Albert J. Mamary, Andrew Gangemi, Jacob Shani, Robert Frankel, Kavita Sharma, Yury Malyshev, Jason Brady, Manan Christian, Gwendolyn Tan-Augenstein, Damian A. Chiandussi, Ann Behne, Mellisa Black, Aldo Bonaventura, Rick Earl Clary, Henley Deutsch, Christina Duke, Joan Greer, Mary Hardin, Mary Harmon, Heather Kemp, Ai-Chen Ho, Ikenna Ibe, Amy Ladd, Amr Marawan, Roshanak Markley, Kim McKee, Virginia Mihalick, Alison Montpetit, James Mbualungu, Joyce O’Brien, Catherine Owen, Mary Pak, Nimesh Patel, William Payne, Anna Priday, Robin Sculthorpe, Melissa Sears, Yub Raj Sedhai, Earl Kenneth Sims, Kathryn Spence, Hilary Tackett, Georgia Thomas, Juanita Turner, Benjamin Van Tassell, Alessandra Vecchiè, George Wohlford

Abstract

Effective treatments for patients with severe COVID-19 are needed. To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19. This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227). The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. ClinicalTrials.gov Identifier: NCT04362813.

Twitter Demographics

The data shown below were collected from the profiles of 115 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 13%
Student > Ph. D. Student 6 11%
Other 6 11%
Researcher 6 11%
Unspecified 3 6%
Other 12 23%
Unknown 13 25%
Readers by discipline Count As %
Medicine and Dentistry 16 30%
Immunology and Microbiology 4 8%
Nursing and Health Professions 4 8%
Agricultural and Biological Sciences 3 6%
Biochemistry, Genetics and Molecular Biology 3 6%
Other 7 13%
Unknown 16 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 157. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2021.
All research outputs
#169,157
of 19,557,897 outputs
Outputs from JAMA: Journal of the American Medical Association
#2,693
of 30,638 outputs
Outputs of similar age
#5,026
of 339,413 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#51
of 276 outputs
Altmetric has tracked 19,557,897 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 30,638 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 68.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,413 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 276 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.